latest news releases from the newsroom
Carmina Technologies Inc.
Carmina Technologies Launches ASSUR Monitoring Product Line -- Improving Mission Critical Quality Control
CALGARY, Alberta, Jan. 29, 2003 (PRIMEZONE) -- Carmina Technologies Inc. (OTCBB:CARL) has launched it's line of ASSUR products which improve and enhance the inspection and quality control process for a variety of industries. President and chief executive officer John Alston said: "With the ASSUR product lines we are bringing tested and developed technology to the market launch. Our ASSUR family of monitoring services provide for a reliable, cost effective system of monitoring the performance of services critical to maintaining quality control and public health and safety."
Northrop Grumman Corp.
Northrop Grumman Corporation Issues Grant for Pilot Training to Re-Create Wright's Flight
WARRENTON, Va., Jan. 29, 2003 (PRIMEZONE) -- The Discovery of Flight Foundation announced today a major gift from Northrop Grumman Corporation for pilot training as preparations continue for the Countdown to Kitty Hawk Celebration on Dec. 17, 2003. On that date, a pilot for The Wright Experience, which is under contract by the Foundation, will attempt to re-create Orville Wright's inaugural 120-feet flight in a precise reproduction of the original plane, 100 years later at the precise location of the original flight on the dunes of the Outer Banks in North Carolina.
Van Lanschot NV
Van Lanschot NV: Important dates in 2003
HERTOGENBOSCH, The Netherlands, Jan. 29, 2003 (PRIMEZONE) -- Van Lanschot NV has set the following dates for the publication of its half-year and annual figures and for the Annual General Meeting of Shareholders: Annual figures for 2002 Friday, March 14, 2003 (before opening of trading: publication of press release).
Asahi Broadcasting Corporation Selects Virage for Digital Newsroom Project
SAN MATEO, Calif., Jan. 29, 2003 (PRIMEZONE) -- Virage, Inc. (Nasdaq:VRGE), a leading provider of video and rich media communication software, today announced that Asahi Broadcasting Corporation has selected Virage to streamline its newsroom production process. Based in Osaka, Asahi Broadcasting is one of Japan's leading broadcasters and is transforming its newsroom from analog to digital. Asahi Broadcasting's staff of journalists, editors, and producers, will be able to access all news content and related media assets, as well as satellite and line feeds, from their desktops.
Occidental Petroleum Corp.
Occidental Petroleum Announces Fourth Quarter 2002 Results
LOS ANGELES, Jan 29, 2003 (PRIMEZONE) -- Occidental Petroleum Corporation (NYSE:OXY) announced net income for the fourth quarter 2002 of $322 million ($0.85 per share), compared with a net loss of $247 million ($0.66 per share) for the fourth quarter 2001. The fourth quarter 2001 included a $240 million after-tax charge, reflecting the effect of the agreement to sell Occidental's interest in Equistar.
Swedia Networks to Supply Network Delivery Services and Maintenance for Nokia in Austria, Germany and Switzerland
STOCKHOLM, Sweden, Jan. 29, 2003 (PRIMEZONE) -- Swedia Networks and Nokia Networks, the infrastructure arm of Nokia (NYSE:NOK), have signed an agreement on network delivery and maintenance services for Nokia's network deployments in three European countries. Under the terms of the agreement, Swedia Networks will provide Nokia Networks with delivery and care services for the mobile networks of its operator customers in Austria, Germany and Switzerland. The agreement also calls for the transfer of 62 Nokia employees to Swedia Networks.
Pharmexa Focuses and Adjusts the Organization
HOERSHOLM, Denmark, Jan. 29, 2003 (PRIMEZONE) -- As first announced on September 10, 2002, Pharmexa (Other OTC:PMXAY) is increasingly focusing its resources on the most advanced products, the HER-2 DNA AutoVac(TM), HER-2 Protein AutoVac(TM) and TNF-alpha AutoVac(TM) products. These three successful development projects continue to demand more resources. A comprehensive phase II trial with HER-2 DNA AutoVac(TM) against breast cancer is currently being prepared in several European countries while HER-2 Protein AutoVac(TM), also against breast cancer, soon commences a phase I trial in the United States. At the same time, the TNF-alpha AutoVac(TM) against rheumatoid arthritis is moving quickly towards clinical trials in man. On this basis and as a result of the poor capital markets, Pharmexa has decided to downgrade a number of research programmes within cancer and allergy. The company's RANKL AutoVac(TM) programme against bone degeneration will be continued on a lower resource level.